Biolinerx LTD. – American Depositary Shares (NASDAQ:BLRX) Short Interest Decreased By 6.45%

May 18, 2018 - By Eva Godbolt

BioLineRx Ltd. (NASDAQ:BLRX) Logo

The stock of Biolinerx LTD. – American Depositary Shares (NASDAQ:BLRX) registered a decrease of 6.45% in short interest. BLRX’s total short interest was 377,000 shares in May as published by FINRA. Its down 6.45% from 403,000 shares, reported previously. With 141,600 shares average volume, it will take short sellers 3 days to cover their BLRX’s short positions. The short interest to Biolinerx LTD. – American Depositary Shares’s float is 0.59%.

The stock increased 3.89% or $0.0345 during the last trading session, reaching $0.9224. About 663,041 shares traded or 169.57% up from the average. BioLineRx Ltd. (NASDAQ:BLRX) has declined 24.35% since May 18, 2017 and is downtrending. It has underperformed by 35.90% the S&P500.

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company has market cap of $97.77 million. The Company’s development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. It currently has negative earnings. The companyÂ’s other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome.

BioLineRx Ltd. (NASDAQ:BLRX) Ratings Coverage

Among 2 analysts covering Biolinerx (NASDAQ:BLRX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Biolinerx had 9 analyst reports since November 21, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, March 6 by H.C. Wainwright. The firm has “Buy” rating given on Tuesday, March 6 by Oppenheimer. The firm has “Buy” rating given on Tuesday, March 20 by Oppenheimer. The firm has “Buy” rating given on Monday, December 4 by H.C. Wainwright. The stock of BioLineRx Ltd. (NASDAQ:BLRX) has “Buy” rating given on Tuesday, November 21 by H.C. Wainwright. The firm earned “Buy” rating on Wednesday, January 17 by H.C. Wainwright. Oppenheimer initiated the stock with “Buy” rating in Thursday, December 21 report. The rating was maintained by Oppenheimer on Monday, December 4 with “Buy”. The firm has “Buy” rating given on Thursday, December 21 by H.C. Wainwright.

More important recent BioLineRx Ltd. (NASDAQ:BLRX) news were published by: Benzinga.com which released: “41 Biggest Movers From Yesterday” on May 17, 2018, also Streetinsider.com published article titled: “BioLineRx (BLRX) Announces Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization”, Prnewswire.com published: “BioLineRx to Present Overall Survival Data at EHA from Phase 2a Study of BL-8040 in r/r AML Patients” on May 17, 2018. More interesting news about BioLineRx Ltd. (NASDAQ:BLRX) was released by: Benzinga.com and their article: “Benzinga Pro’s 5 Stocks To Watch Today” with publication date: May 16, 2018.

BioLineRx Ltd. (NASDAQ:BLRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: